USHA KARTAN: Open Payments
NPI 1689720310 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$879 in 32 payments from 11 companies in 2025. Trend: 2023 $883 · 2024 $672 · 2025 $879
Food & beverage: $767Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $223 |
| Lundbeck LLC | 7 | $159 |
| Otsuka America Pharmaceutical, Inc. | 4 | $108 |
| Neurocrine BioSciences, Inc. | 3 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $75 |
| Alkermes, Inc. | 3 | $73 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| ABBVIE INC. | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
Products named: REXULTI, INGREZZA, UZEDY, CAPLYTA, ARISTADA, HETLIOZ, VRAYLAR, AUSTEDO XR.
Industry payments across IL — which companies pay providers there.
